Antonio Garcia Guiñon
Degree: Graduate
973 705351
agarciag.lleida.ics(ELIMINAR)@gencat.cat
Groups
Publications
-
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Clinical Epigenetics 13 9-9. .
-
Oriol A; Ibarra G; Abella E; Motlló C; Cibeira MT; Garcia A; Escoda L; Granell M; Ben-Azaiz R; Cervera M; Cabezudo E; Fernandez C; Rosiñol L
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma.
LEUKEMIA & LYMPHOMA 62 1-11. .
-
Ribera, JM; Garcia, O; Chapchap, EC; Gil, C; Gonzalez-Campos, J; Barba, P; Amigo, ML; Moreno, MJ; Lavilla, E; Alonso, N; Bergua, JM; Tormo, M; Ribera, J; Sierra, M; Martinez-Carballeira, D; Mercadal, S; Hernandez-Rivas, JM; Vall-Llovera, F; Genesca, E; Cladera, A; Novo, A; Abella, E; Garcia-Cadenas, I; Monteserin, C; Bermudez, A; Piernas, S; Montesinos, P; Lopez, JL; Garcia-Guinon, A; Serrano, A; Martinez, MP; Olivares, M; Lopez, A; Serrano, J; PETHEMA Grp; Spanish Soc Hematology
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy
Clinical Lymphoma Myeloma & Leukemia 20 513-. .
-
Genescà E; Morgades M; Montesinos P; Barba P; Gil C; Guàrdia R; Moreno MJ; Martínez-Carballeira D; García-Cadenas I; Vives S; Ribera J; González-Campos J; González-Gil C; Zamora L; Ramírez JL; Díaz-Beya M; Mercadal S; Artola MT; Cladera A; Tormo M; Bermúdez A; Vall-Llovera F; Martínez P; Amigo ML; Monsalvo S; Novo A; Cervera M; García-Guiñon A; Juncà J; Ciudad J; Orfao A; Ribera JM
Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia.
HAEMATOLOGICA 105 294-297. .
-
Ribera, JM; Morgades, M; Montesinos, P; Tormo, M; Martinez-Carballeira, D; Gonzalez-Campos, J; Gil, C; Barba, P; Garcia-Boyero, R; Coll, R; Pedreno, M; Ribera, J; Mercadal, S; Vives, S; Novo, A; Genesca, E; Hernandez-Rivas, JM; Bergua, J; Amigo, ML; Vall-Llovera, F; Martinez-Sanchez, P; Calbacho, M; Garcia-Cadenas, I; Garcia-Guinon, A; Sanchez-Sanchez, MJ; Cervera, M; Feliu, E; Orfao, A
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
Cancer Medicine 9 2317-2329. .
-
Ribera J; Granada I; Morgades M; Vives S; Genescà E; González C; Nomdedeu J; Escoda L; Montesinos P; Mercadal S; Coll R; González-Campos J; Abella E; Barba P; Bermúdez A; Gil C; Tormo M; Pedreño M; Martínez-Carballeira D; Hernández-Rivas JM; Orfao A; Martínez-López J; Esteve J; Bravo P; Garcia-Guiñon A; Debén G; Moraleda JM; Queizán JA; Ortín X; Moreno MJ; Feliu E; Solé F; Ribera JM
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients
BRITISH JOURNAL OF HAEMATOLOGY 186 263-268. .
-
Cabezón M; Bargay J; Xicoy B; García O; Borrás J; Tormo M; Marcé S; Pedro C; Valcárcel D; Jiménez MJ; Guàrdia R; Palomo L; Brunet S; Vall-Llovera F; Garcia A; Feliu E; Zamora L
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Oncotarget 9 19342-19355. .
-
Guillem, V; Calabuig, M; Brunet, S; Esteve, J; Escoda, L; Gallardo, D; Ribera, JM; Queipo de Llano MP; Arnan, M; Pedro, C; Amigo, ML; Marti-Tutusaus, JM; Garcia-Guinon, A; Bargay, J; Sampol, A; Salamero, O; Font, L; Talarn, C; Hoyos, M; Diaz-Beya, M; Garrido, A; Navarro, B; Nomdedeu, J; Sierra, J; Tormo, M
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival
LEUKEMIA & LYMPHOMA 59 2383-2393. .
-
Nomdedéu JF; Puigdecanet E; Bussaglia E; Hernández JJ; Carricondo M; Estivill C; Martí-Tutusaus JM; Tormo M; Zamora L; Serrano E; Perea G; de Llano MP; García A; Sánchez-Ortega I; Ribera JM; Nonell L; Aventin A; Solé F; Brunet MS; Sierra J
Feasibility of the AML profiler (Skyline (TM) Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach
HEMATOLOGICAL ONCOLOGY 35 778-788. .
-
Sanchez, R; Ayala, R; Alberto Alonso, Rafael; Pilar Martinez, Maria; Ribera, J; Garcia, O; Sanchez-Pina, J; Mercadal, S; Montesinos, P; Martino, R; Barba, P; Gonzalez-Campos, J; Barrios, M; Lavilla, E; Gil, C; Bernal, T; Escoda, L; Abella, E; Luz Amigo, Ma; Jose Moreno, Ma; Bravo, P; Guardia, R; Hernandez-Rivas, JM; Garcia-Guinon, A; Piernas, S; Ribera, JM; Martinez-Lopez, J
Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid
ANNALS OF HEMATOLOGY 96 1069-1075. .
-
Sierra, J.; Garrido, A.; Diaz-Beya, M.; Vives, S.; Pomares, H.; Guardia, R.; Cervera, M.; Queipo de Llano, M.; Salamero, O.; Garcia, A.; Marti-Tutusaus, J.; Pedro, C.; Bargay, J.; Sampol, A.; Hoyos, M.; Pratcorona, M.; Escoda, L.; Gallardo, D.; Arnan, M.; Ribera, J.; Esteve, J.; Nomdedeu, J.; Brunet, S.
ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS
HAEMATOLOGICA 102 49-49. .
-
Garrido, A.; Brunet, S.; Calabuig, M.; Diaz-Beya, M.; Vives, S.; Cervera, M.; Pomares, H.; Guardia, R.; Salamero, O.; Queipo de Llano, M.; Bargay, J.; Sampol, A.; Pedro, C.; Garcia, A.; Marti-Tutusaus, J.; Heras, I.; Torres, P.; Font, L.; Gonzalez, J.; Hernandez, D.; Hoyos, M.; Gallardo, D.; Arnan, M.; Escoda, L.; Ribera, J.; Esteve, J.; Tormo, M.; Nomdedeu, J.; Sierra, J.
FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70
HAEMATOLOGICA 102 322-323. .
